尼克酰胺N-甲基转移酶作为潜在的肿瘤标志物的研究进展  

Research advances in nicotinamide N-methyltransferase as a potential tumor biomarker

作　　者：周艳文[1,2] 李贵玲[1,2] 王燕忠[1,2] 张钧[1,2] 谢鑫友[1,2] 

机构地区：[1]浙江大学医学院附属邵逸夫医院检验科,浙江杭州310016 [2]浙江省生物治疗重点实验室,浙江杭州310016

出　　处：《肿瘤》2013年第7期648-652,共5页Tumor

基　　金：国家自然科学基金资助项目(编号:81271914);浙江省自然科学基金资助项目(编号:LY12H16025);浙江省科技厅重大科技专项基金资助项目(编号:2012C13019-2);浙江省卫生厅科研资助项目(编号:2011KYA081;2008B114);浙江省教育厅科研资助项目(编号:Y201121182)

摘　　要：已知临床应用肿瘤标志物可有效提高肿瘤的早期诊断、预后判定和靶向治疗效果。近年来,基因芯片和蛋白组学技术的广泛开展有力地推动了新的肿瘤标志物的发现和鉴定。尼克酰胺N-甲基转移酶(nicotinamide N-methyltransferase,NNMT)即是在这些技术的推动下新近被筛选并鉴定的蛋白之一,其在多种肿瘤组织中差异表达,且研究发现它与肿瘤细胞增殖、转移及耐放化疗等多种特征性生物学功能密切相关,提示NNMT可作为潜在的肿瘤辅助诊断、个体化和靶向治疗的标志物。本文就NNMT作为潜在的肿瘤标志物的最新研究进展进行综述。The clinical application of tumor markers has effectively improved the early diagnosis, prognosis and the response to targeted therapy in patients with tumors. Proteomic technologies and DNA microarrays have provided useful tools needed to discover and identify novel tumor biomarkers. Recently, NNMT （nicotinamide N-methyltransferase） was identified and verified as a dysregulated protein in various cancers through these technologies. NNMT is closely correlated to various biological functions of tumor cells, such as proliferation, metastasis and resistance to chemotherapy and radiotherapy, suggesting it may be used as a new tumor marker for auxiliary diagnosis, individualized treatment and targeted therapy. This review summarizes the latest advances in the research of NNMT used as a potential tumor biomarker.

关 键 词：肿瘤形成过程 烟酰胺N-甲基转移酶 生物学标志 药理学 早期诊断 预后 肿瘤治疗方案 

分 类 号：R730.45[医药卫生—肿瘤] R730.51[医药卫生—临床医学]